Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasms 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × irinotecan sucrosofate × Tumor-Agnostic × Clear all
NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡